

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents Washington, D.C. 20231 on May 6, 2002

1743
CLAIM OF PRIORITY UNDER 35 USC §119
Examining Group 1743
Patent Application
Docket No. GJE-87
Serial No. 10/081,599

David R. Saliwanchik
David R. Saliwanchik, Patent Attorney



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1743
Applicants : Cornelia Anna Mundt, Marianne Brueggemann
Serial No. : 10/081,599
Filed : February 20, 2002
Conf. No. : 9658
For : Immunoglobulin Control Region

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED
MAY 20 2002
TC 1700

CLAIM OF PRIORITY UNDER 35 USC §119

Sir:

The applicants in the above-identified patent application hereby reaffirm their claim to the right of priority granted pursuant to 35 USC §119 based upon Great Britain Application No. 0104299.3, filed February 21, 2001.


As required by the Statute, a certified copy of the Great Britain application is being submitted herewith. The applicants request that this certified copy of the foreign priority application be made of record in the subject application pursuant to MPEP 201.14(b).


Respectfully submitted,

David R. Saliwanchik
David R. Saliwanchik
Patent Attorney
Registration No. 31,794
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: 2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

DRS/la

Attachments: Certified copy of priority document GB 0104299.3





1/77

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
South Wales
NP9 1RH

1. Your reference	REP06658GB		
2. Patent application number (The Patent Office will fill in this part)	21 FEB 2001	0104299.3	
3. Full name, address and postcode of the or of each applicant (<i>underline all surnames</i>)	The Babraham Institute Babraham Hall Babraham Cambridge CB2 4AT 07444519001 United Kingdom		
Patents ADP number (<i>if you know it</i>) If the applicant is a corporate body, give the country/state of its incorporation			
4. Title of the invention	IMMUNOGLOBULIN CONTROL REGION		
5. Name of your agent (<i>if you have one</i>)	Gill Jennings & Every		
"Address for service" in the United Kingdom to which all correspondence should be sent (<i>including the postcode</i>)	Broadgate House 7 Eldon Street London EC2M 7LH		
Patents ADP number (<i>if you know it</i>)	745002		
6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (<i>if you know it</i>) the or each application number	Country	Priority application number (<i>if you know it</i>)	Date of filing (<i>day / month / year</i>)
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of filing (<i>day / month / year</i>)	
8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (<i>Answer 'Yes' if:</i> a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body. See note (d))	YES		

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 29

Claim(s) 1

Abstract

Drawing(s) 9 + 8/11

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

NO

11. For the applicant
Gill Jennings & Every

I/We request the grant of a patent on the basis of this application.

Signature

Date

21 February 2001

12. Name and daytime telephone number of person to contact in the United Kingdom

PERRY, Robert Edward

020 7377 1377

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

IMMUNOGLOBULIN CONTROL REGION

Field of the Invention

This invention relates to a control region in human immunoglobulins, to parts thereof and to their use.

Background of the Invention

The human IgH locus contains nine functional C genes and two pseudogenes, arranged 5' C μ -C δ -C γ 3-C γ 1- ψ C ϵ -C α 1- ψ C γ -C γ 2-C γ 4-C ϵ -C α 2 3', over a 350 kb region of chromosome 14 (1). Overlapping phage and cosmid clones established the C gene organisation but attempts to obtain the entire region on overlapping clones or a single yeast artificial chromosome (YAC)⁵ have been unsuccessful (ref. 2 and our own results). PCR-based approaches identified highly repetitive regions downstream of C α 1 and C α 2 which include virtually identical 3' enhancers made up from different numbers of short motifs (3, 4). Similar repetitiveness, leading to instability, was also assumed for the estimated 40-70 kb gap between C δ and C γ 3, which could not be cloned to establish a C gene contig. Indirect results from transgenic mice lacking different regions 3' of C μ and C δ further suggested that this particular downstream region might be important for high expression and switching of IgH genes (5, 6). Analysis of recombination in the C δ -C γ 3 interval showed a lack of association between these genes, which may indicate a potential hot spot for recombination (7, 8). The potential significance of this region is further supported by the finding that a large area between C δ and C γ 3 is deleted in certain leukemias, which may be linked to a pathogenic mechanism active at an early stage of B-cell development (9).

In the mouse, the IgH locus has been completely cloned (10), and in DNA-binding assays a cluster of matrix association regions (MARs) was found in the C δ -C γ 3 intron (11). Although the region was not extensively characterized by sequencing, the presence of long interspersed repetitive elements in the vicinity of MARs may lead to the high recombination observed in this region of the IgH locus. Probes derived from bacteriophage clones covering the mouse C δ -C γ 3 region failed to identify corresponding sequences in the human locus (9). During B lymphocyte development it is generally thought that transcriptional activation of

the IgH locus is regulated using two enhancer arrays which flank the constant region cluster (12-14, reviewed in 15). These arrays, the E μ intron enhancer and the 3' enhancer downstream of C α , contain multiple sites for the binding of both tissue specific and ubiquitous trans-acting factors (13, 16). Enhancer-mediated activation appears to be controlled by the interaction of both negative and positive regulatory elements (17, 18). The E μ intron enhancer provides potential protein binding sites for several regulatory elements which are essential for lymphocyte differentiation, including E47, PU.1, Ets-1, TFE3, USF and Oct (19, 20). The 3' α enhancer shares some DNA sequence elements with the E μ enhancer but also has additional motifs for factors involved in transcriptional regulation (13, 16). Activation and sequential DNA rearrangement of the Ig loci are crucial steps in antibody expression and *cis*-acting locus elements like enhancers, which accommodate various combinations of factor binding sites, have been implicated in IgH locus recombination and transcription (17). Although important information about enhancer core functions has been obtained from mutant mouse strains, these are poorly understood processes as there appears to be no activity of either enhancer in early B-cell development when IgH heavy chain rearrangement is initiated. For example, deletion of the heavy chain intron enhancer E μ showed severe impairment of V H to D JH rearrangement whilst the earlier D to J H rearrangement was much less affected (21). In chimeric mice, in which the C α 3' enhancer was replaced by a marker gene, isotype deficiency and impairment of heavy chain class-switching was observed (18).

Summary of the Invention

The region between C δ and C γ 3, of IgH is unstable and may be a recombination hot spot; it has now been shown that 21 kb of the unstable region in the human IgH locus between C δ and C γ 3 contains a highly clustered array of a large number of transcription factor binding motifs interspersed with repeat sequences. Transfection assays revealed transcription enhancement and silencing activity at the pre B-cell stage and in transgenic mice strong enhancer function was identified in the bone marrow, the primary site of B-cell differentiation. Flow cytometry analysis of early B-cell populations showed that

this enhancer is already active at the pro/pre B-cell stage where DNA rearrangement is initiated. The region accommodating E δ - γ 3 may exert locus control function at an early developmental stage, which may be critical in normal and aberrant B-cell development.

In particular, a pBAC clone (pHulGH3 δ - γ 3) has been isolated, that established a 52 kb distance between C δ and C γ 3. Sequence analysis identified a high number of repeat elements, explaining the instability of the region, and an unusually large accumulation of transcription factor binding motifs, both for lymphocyte-specific and ubiquitous transcription activators (IKAROS, E47, Oct-1, USF, Myc/Max), and for factors which may repress transcription (DeltaEF1, Gfi-1, E4BP4, C/EBP β). Functional analysis in reporter gene assays revealed the importance of the C δ -C γ 3 interval in lymphocyte differentiation, and identified independent regions capable of either enhancement or silencing of reporter gene expression, and interaction with the IgH intron enhancer E μ . In transgenic mice, carrying a construct which links the β -globin reporter to the novel δ - γ 3 intron enhancer (E δ - γ 3), transgene transcription is exclusively found in bone marrow B-cells from the early stage when IgH rearrangement is initiated up to the successful completion of H and L locus recombination resulting in antibody expression. These findings suggest that the C δ -C γ 3 interval exerts regulatory control on immunoglobulin gene activation and expression during early lymphoid development.

According to a first aspect of the invention, the C δ -C γ 3 region is stable in an artificial chromosome or non-human animal. It can thus be used to produce a repertoire of human antibodies or antibody fragments in a non-human animal; the functional characteristics of the region, including effective enhancer sequences, can provide a wider and more useful repertoire than has previously been possible.

According to a second aspect of the invention, a functional enhancer and/or silencer sequence within the C δ -C γ 3 region (of the human or non-human IgH locus) can be used as such, e.g. in a heterologous construct, to enhance the

expression of a heterologous gene. For this purpose, the repeat sequences that give the C δ -C γ 3 region its instability are not needed.

Description of the Invention

Materials and methods

BAC library construction

A size-selected library was constructed from human DNA using the pBeloBACII vector (22). An MluI linker was added to the pBeloBACII vector following linearisation with SphI in the multiple cloning site. Human genomic DNA was prepared from the fibroblast cell line KB (23) and digested to completion with MluI. The fragments were size fractionated by Pulsed Field Gel Electrophoresis (PFGE) in 1% low melting temperature agarose (SeaPlaque FCM, USA) at 12V/cm in 0.5 x TBE with a 40 sec pulse for 24 h at 3.5°C. Gel slices containing DNA fragments from ~30-80 kb were excised, melted at 67°C and digested for 1 h at 40°C with 1 unit Gelase (Epicentre, USA) per 0.1 g of gel. Size selected DNA (100-200 ng) was ligated with dephosphorylated MluI restricted pBeloBACII vector (25-50 ng) using 4 units T4 ligase (NEB, Canada). Ligation mixtures were dialysed against 3 ml TE and 1mM polyamines for 4 h at room temperature using Millipore filters 30000 NMWL (Millipore, USA). Aliquots of the dialysed ligation mixture (1 μ l) were used to transform *E. coli* DH10B by electroporation at 120 V, 25 μ F, and 100 Ohms (24). Transformed cells were incubated for 90 min at 37°C in SOC medium, shaking at 250rpm, and plated on LB-agar containing 12.5 μ g/ml chloramphenicol, 50 μ g/ml X-Gal, and 25 μ g/ml IPTG. Distinguishable white and blue colonies appeared after 24h, and about 5000 white clones were isolated and analysed by colony-filter hybridization with the 0.4 kb EcoRI fragment of pM5-1-23 (25) and human C γ 3 (ref. 26 and see below). The insert size was determined by MluI digest and PFGE.

Hybridization and sequencing

For hybridization analysis, genomic DNA (10 μ g) or pBAC DNA (0.5 ng), was digested with the desired restriction enzyme and separated on 0.8 % agarose gels in TAE. DNA was transferred to nylon membranes (Hybond-N, Amersham) by alkaline transfer and the blots were hybridized with oligolabelled

probes at 65°C in Church Buffer. Hybridization probes were a 7.4 kb HindIII fragment containing human $\gamma 3$ (26) and a 0.4 kb EcoRI fragment obtained from a 3.4 kb BamHI fragment located ~20 Kb downstream of human C δ from the 3' end of the HulgH YAC, derived by plasmid rescue after digestion (clone pM5-1-23, ref. 25). The 5.9 kb BamHI fragment of pHulgH3' δ - $\gamma 3$ (see Fig. 1) was subcloned and a 0.5 kb SspI-BamHI fragment was derived therefrom for further mapping.

Sequencing was performed by the Babraham Microchemical Facility using an ABI Model 373 automated sequencer. Sequence information was obtained using vector-specific primers to analyse restriction fragments subcloned in pUC19 or overlapping fragments obtained by exonuclease III digestion of fragments (Erase-a-Base System, Promega, UK), and also by custom oligonucleotides based on initial sequence information.

Cell lines and transfection assay

The cell lines used for the reporter gene analysis were from the Institute's collection or a kind gift from collaborators and their origin is described in the American Tissue Culture Collection catalog. The human cell lines used were NALM-6 pre B-cells, DG-75 plasma cells, Jurkat T lymphoblast cells and KB fibroblasts (27 and references therein, 28, 29, 23), and the mouse cell lines were 3-1 and 18-81 pre B-cells and the plasma cell lines MPC11 (producing IgG2b) and AH (producing IgM) (30). The cell lines were maintained in RPMI (Gibco, UK) supplemented with 10% FCS and 50 μ M β -mercaptoethanol.

Transcriptional activity of fragments from the pHulg3' δ - $\gamma 3$ -5' region was analysed with a luciferase reporter assay system according to the manufacturer's protocol using a BioOrbit 1253 Luminometer (Promega, UK). The pGL3 vector ensures low background luciferase expression and this allowed the unambiguous measurement of enhancer function. The overlapping fragments from the pHulg3' δ - $\gamma 3$ 5' region (see Figs. 1 and 5) tested were: 1) 10.7 kb MluI-HindIII; 2) 7.2 kb MluI-BamHI; 3) 8.5 kb HindIII; and 4) 5.9 kb BamHI. These were inserted 5' of the SV40 promoter of the pGL3 reporter gene construct. The size of fragment 2 in the reporter gene construct was reduced by creating the necessary 5' and 3' overhang by MluI and KpnI restriction and exonuclease III treatment. As

a positive control, pGL3 control vector containing the SV40 enhancer was used. To test the interaction with other IgH enhancers, the human E μ intron enhancer (25) was added 5' of an inserted fragment. Pre B-cells, pro B-cells, Jurkat and KB fibroblasts (2.5×10^6) were transfected by electroporation using 7 μ g pGL3 containing fragment 1, 2, 3 or 4 with or without E μ and with 1 μ g pSV- β -galactosidase control plasmid as an internal standard. Electroporation conditions were 960 μ F, 200 Ohms and 270-300V. Cells were harvested after 20-22h incubation. Plasma cells ($1-3 \times 10^5$) were transfected with the above constructs by lipofection with DOTAP (Boehringer, Mannheim, Germany) according to the manufacturer's protocol. The β -galactosidase assay was performed in 100 μ l reaction buffer (0.1M Na $_2$ HPO $_4$ /NaH $_2$ PO $_4$ pH7.3; 1mM MgCl $_2$; 50 mM β -mercaptoethanol; 1.33 mg/ml o-nitrophenyl- β -D-galactopyranoside) for 30-120 min. The reaction was stopped with 150 μ l 1M Na $_2$ CO $_3$, and the conversion of substrate was measured in a Titertek Multiscan MCC/340 at 410 nm.

Transgene expression analysis

The 1.3 kb E δ - γ 3 fragment (position 5885 to 7185 in pGL3) obtained by PCR was added to a 3 kb human β -globin gene subcloned in pUC12 (31) by blunt end ligation into the XbaI site in the linker. A ~4.3 kb SacI-HindIII DNA fragment containing E δ - γ 3 linked to the β -globin reporter gene was gel purified and injected into the pronuclei of fertilised (C57BL/6xCBA)F1 eggs at 1-2 pg/ml (32). Transgenic mice were obtained with high and low copy number verified by tail blot analysis with a transgene probe. RNA from different tissues was prepared as described by the manufacturer using the RNAqueous Kit (Ambion, UK) or the RNazol B method (AMS Biotechnology, Oxford, UK) for bone marrow. Cell preparations were essentially free of erythrocytes with the exception of liver cells where a low percentage remained. Hybridization probes were the β -globin transgene and a 540 bp actin gene fragment obtained by PCR (33). For the isolation of B-cell subpopulations by flow cytometry bone marrow cells were stained as described (34). Multicolor staining was carried out with the following reagents in combinations shown in Fig. 7B: PE (phycoerythrin)-conjugated anti-mouse CD25 (P3317, Sigma), PE-conjugated anti-mouse CD45R (B220) (P3567,

Sigma), biotinylated anti-mouse IgM (No. 02082D, PharMingen), PE-conjugated anti-mouse *c-kit* (CD117) (No. 09995B, PharMingen), FITC-conjugated anti-mouse CD19 (No. 09654D, PharMingen), FITC-conjugated anti-mouse IgD (No. 02214D, PharMingen) and biotinylated anti-mouse CD43 (No. 01602D, PharMingen). Binding of biotinylated antibody was developed with streptavidin quantum red (S2899, Sigma). The oligonucleotides for RT-PCR of β -globin and HPRT as a control have been described (31). RT-PCR was performed with the One-Step System (GibcoBRL) under the following conditions: 50°C for 30 min followed by 94°C for 2 min for cDNA synthesis, followed by 30 PCR cycles (15 sec 92°C, 30 sec 55°C, 30 sec 72°C) and 5 min at 72°C to complete the reaction.

Results

The distance between C δ and C γ 3 is 52 kb

Southern blot analysis suggested that the region between C δ and C γ 3 is 40-70 kb in size (1, 8). We analysed human sperm DNA and the human fibroblast cell line KB (23) by digestion with rare cutting enzymes and hybridization with probes from the 3' end of the human IgH YAC and from human C γ 3 (see Fig. 1). Southern blots of MluI digests showed a possible region of ~50 kb capable of spanning the gap between C δ -C γ 3 (data not shown). A size selected bacterial artificial chromosome (BAC) library was constructed and hybridized with the 0.4 kb EcoRI fragment of pM5-1-23, from the 3' end of the IgH YAC (25), and human C γ 3 (26). Of eight clones, pHuIgH3' δ - γ 3, hybridized with both of these probes and MluI restriction digestion followed by Pulsed Field Gel Electrophoresis (PFGE) identified a 48 kb insert. Comparison of the restriction patterns of pHuIgH3' δ - γ 3 with the HuIgH YAC (5) and coslg6 (35) revealed substantial homologies at the 5' and 3' ends respectively, which suggested that pHuIgH3' δ - γ 3 spanned the gap between the C δ and C γ 3 constant region genes (Fig. 1A). The 5' MluI cloning site of pHuIgH3' δ - γ 3 lies ~4 kb 3' of the δ membrane exon 2, a region not yet characterized by sequence analysis, whilst the 3' MluI cloning site is located in the hinge region of C γ 3 (36). Alignment of restriction maps of pHuIgH3' δ - γ 3 with the HuIgH YAC and coslg6 identified a novel 11 kb region.

To verify that this novel region is in the correct genomic configuration, different digests of human DNA and pHulGH3' δ - γ 3 DNA were analysed in Southern blots using different hybridization probes. An example (Fig. 1B) shows that hybridization with the 0.5 kb SspI-BamHI fragment from pHulGH3' δ - γ 3 identified a 5.9 kb BamHI fragment and a 8.5 kb HindIII fragment both of which are present in human genomic DNA and pHulGH3' δ - γ 3. The C δ proximal BamHI site and the C γ 3 proximal HindIII site of the hybridization fragments are also present on the IgH YAC and cos Ig6, respectively. These results confirm that the cloned region on pHulGH3' δ - γ 3 completes the C δ -C γ 3 sequence gap and establishes the distance between C δ m2 and C γ 3 as 52 kb.

The C δ -C γ 3 interval region is highly repetitive

The nucleotide sequence of the C δ proximal 5' region of pHulGH3' δ - γ 3 (EMBL no. to be added), indicated in Fig. 1A by the hatched line, was determined by subcloning of overlapping fragments, exonuclease III digestion and primer walking. Self-alignment of this 21 kb region (Fig. 2A) identified many regions of similarity as Alu motifs (37), with a pronounced cluster at the 3' end (Fig. 2B) that incorporated several residual fragments of Alu motifs as well as complete motifs, in various orientations. In addition, we found transposon-like elements (LINE, LTR etc.) in abundance and of different complexity (38-40); three 40 bp MstII-like repeats were arranged in a tandem configuration, which may highlight transposon activity, and a 76 bp region comprising 23 (CT) repeats was followed immediately by 15 (AT) repeats. The CT and AT repeats encode the amino acids pairs Leu/Ser and Ile/Tyr independently of the reading frame. The presence of this large number of repetitive elements may be the reason for the instability of the locus observed during cloning efforts.

A cluster of transcription factor recognition motifs

Potential binding factor recognition sites of regulatory proteins were identified by comparison of the pHulGH3' δ - γ 3 sequence with the TRANSFAC transcription-factor database using Matinspector (41, 42). As shown in Fig. 3, many binding motifs were represented very frequently despite the high score used for the database search, which was 1.0 for core similarity and 0.90 or

greater for matrix similarity. The transcription factors identified can operate either to enhance or suppress immunoglobulin transcription, and many are also present in the E μ and 3' α enhancer regions (reviewed in ref. 43, 44). Binding sites were found for the activating proteins Ikaros, E47, Oct1, USF and Myc/Max (45-51). The Ikaros gene products belong to the group of zinc finger DNA binding proteins (52) and have a complex role in the early stages of lymphocyte development with establishing the maintenance and differentiation of multipotent progenitors (53). In the group of repressor proteins, binding sites for DeltaEF1, Gfi-1, E4BP4 and C/EBP β were identified (54-57). The potential binding-site of the nuclear zinc finger protein Gfi-1 (growth factor independence 1) has been identified in a large number of eukaryotic promoter-enhancers (58, 59).

No similar large accumulation of different binding protein recognition sites was evident when other regions of the immunoglobulin H and L chain introns, including known enhancer regions, were examined. The presence of such an extensive and varied cluster of transcription factor binding motifs may suggest that the region between C δ and C γ 3 exerts previously unrecognised Ig locus control function.

Pre B-cell specific enhancer activity downstream of C δ

To determine any functional significance of the C δ -C γ 3 interval in development and whether the region contained new cis-acting regulatory sequences we analysed transcriptional promoter activity of subcloned fragments from pHuIgH3' δ - γ 3 using the luciferase reporter gene assay. The analysis identified a 7.2 kb MluI-BamHI fragment from the 5' C δ proximal region which showed good enhancer activity in human and mouse pre B-cells (NALM-6 and 3-1) when placed 5' of the luciferase reporter, but did not promote luciferase activity in human or mouse plasma cells (Figs. 4 and 5). As other fragments did not exhibit B-cell specific enhancer activity we wondered if the failure to demonstrate enhancer activity in Ig2b producing MPC11, in which the C δ -C γ 3' intron regions are deleted, was a consequence of the IgH locus having undergone isotype switching in this cell line. This was not the case as IgM producing AH myeloma cells produced very similar results for all fragments (data not shown). In addition,

the orientation of the subcloned fragments did not alter their functional activity and enhancer function of the MluI-BamHI fragment in pre B-cells was maintained in both transcriptional orientations.

To determine the precise location of this novel IgH δ - γ 3 intron enhancer we dissected the MluI-BamHI fragment by MluI and exonuclease digestion which removed the 5' region and resulted in various smaller size fragments (Fig. 4A). In murine pre B-cells, enhancer activity of the whole region (position 1-7185) exceeds that of the E μ enhancer but the most dramatic increase, twice the activity of E μ , was obtained with a 1.3 kb fragment from position 5885 to 7185 (Fig. 4B). In comparison to mouse cells human NALM-6 pre B-cells showed marked reductions in transcriptional activation. This may simply be a reflection of reduced transfection efficiencies of the human cells but could also indicate concerted interaction of several functional motifs which are recognized differently in mouse and human pre B-cells. However, the strongest transcriptional activation in both human and mouse pre B-cells was obtained by the fragment from position 5885-7185. Comparable enhancer activities, dependent on the developmental stage of the cell rather than its species of origin, agrees with what has been found for other human Ig enhancers analysed *in vitro* and in transgenic mice (31, 60, 61). No enhancer activity was obtained at the later developmental stage of the plasma cell (Fig. 4C). In addition, neither fibroblasts (as control cells) nor T lymphocytes showed any enhancer activity (data not shown). These results from reporter gene transfection assays define a novel region which we named E δ - γ 3 with strong cis-acting enhancer function operative at the pre B-cell stage.

A transcription silencer is located adjacent to the enhancer

The proximity of E μ and E δ - γ 3 led us to speculate about possible enhancer co-operation during B-cell development. For this we added the human E μ intron enhancer to 4 separate but overlapping fragments of the 21 kb sequenced 5' region of pHuIgH3' δ - γ 3 and measured transcriptional activity in luciferase reporter assays (Fig. 5). It is interesting to note that except in one combination (E μ + fragment 1) enhancer activity remained by and large as identified in single enhancer/fragment constructs analysed in B-cell subsets. This

suggests separate functions of $E\mu$ and $E\delta\gamma 3$ and that their enhancer activities are not simply additive. Enhancer activity was maintained when $E\mu$ was combined with fragments 2, 3 and 4, whilst the combination of $E\mu$ with fragment 1 completely abolished enhancer activity in pre B-cells and significantly reduced enhancer activity in plasma cells (Fig. 5B). This suggests that fragment 1 contains a B-cell specific transcription silencer which is likely to be located at the 3' end of fragment 1. Fragment 4 shares a corresponding region and this may explain why transcription levels are somewhat reduced in pre B-cells when coupled to $E\mu$. Furthermore, fragment 1 contains the silencer in close proximity to the $E\delta\gamma 3$ enhancer identified on fragment 2. Thus, the lack of enhancer activity of fragment 1 can be explained by the presence of a strong B-cell specific silencer in this region. It emerged that further dissection of the fragments was ineffective, as $E\delta\gamma 3$ enhancer and silencer activity was reduced or abolished, and suggests that recognition motif combinations are essential. The results show that the 5'C δ -C $\gamma 3$ region accommodates a previously unidentified B-cell specific enhancer-silencer array which may interact with $E\mu$ to control Ig expression during developmental processes. However, the many varied sequence recognition motifs in the C δ -C $\gamma 3$ interval, together with the coordinated enhancer interaction identified, indicate a more complex activity with perhaps other transcription modifiers.

In transgenic mice $E\delta\gamma 3$ is active in the developing B-cell

To determine *in vivo* specificity of the novel enhancer we constructed a transgene composed of $E\delta\gamma 3$ linked to human β -globin as a reporter gene (Fig. 6A). A high and a low copy number transgenic mouse line with head to tail integration of the transgene was identified by Southern blot (Fig. 6B) and RNA was prepared from different tissues for Northern analysis and RT-PCR. For the assays actin or HPRT transcripts were used as internal controls. In Northern hybridization we were surprised to find β -globin expression in the bone marrow and not in other B-lineage tissue (Fig. 6C) which suggests an essential role of $E\delta\gamma 3$ in B-cell development. We then used RT-PCR as a more sensitive method to analyse various B-lineage, T-lineage and non-lymphoid tissues. The result was

the same, the E δ - γ 3 driven transgene is silent in all non-lymphoid tissue as well as in the T-cell compartment, and extensive β -globin specific transcription is only found in bone marrow RNA. These results and the *in vitro* reporter gene assays suggest differentiation stage specific activity of E δ - γ 3 from pro B-cell development (initiation of DNA rearrangement) to mature B-cell (surface IgM) prior to migration from the bone marrow.

To identify differentiation stage specific cell populations in which E δ - γ 3 is active we used flow cytometry and RT-PCR (Fig. 7). The progressive stages in B-cell development are well characterized by cell surface markers and DNA configuration (62). We isolated several distinct cell populations from the bone marrow identified by staining with labelled antibodies specific for the B-cell markers B220 or CD19 in combination with specific antibodies for *c-kit* and CD43 (pro B and pre B-I stage), CD25 (pre B-II stage) and IgM/IgD (immature to mature B-cell) (Fig. 7B). RT-PCR identified β -globin activity in B220⁺ or CD19⁺ B-cells from bone marrow up to the immature IgM⁺IgD⁺ population which has completed the DNA rearrangement process. Transgene activity may be initiated at the early pro B-cell stage in *c-kit*⁺ B220⁺ cells where a faint β -globin specific PCR band (relative to the HPRT signal obtained in the same reaction) was found. As the number of *c-kit*⁺CD19⁺ cells was very low this result may have been obtained from a small cross-contamination of the more abundant CD19⁺ cell population. However, at the stage when DNA rearrangement, D to J_H joining, is initiated in *c-kit*⁺CD19⁺ and CD43⁺B220⁺ B-cells (63) the E δ - γ 3 enhancer is active. H chain and largely L chain rearrangement is finalised at the immature B-cell stage and cells expressing surface IgM show that E δ - γ 3 driven β -globin expression is extinguished at this maturation stage. This concludes that the E δ - γ 3 enhancer is active at the earliest DNA rearrangement event and silent when the rearrangement process (V-D-J for the H chain and V-J for a L chain) has been successfully completed.

Discussion

Instability of the C δ -C γ 3 interval

Use of the BAC cloning system, capable of maintaining highly repetitive large insert DNA (22, 64), enabled us to establish the distance between C δ m2 and C γ 3 as 52 kb. Southern analysis and alignment of pHuIgH3' δ - γ 3 with the 3' end of the HuIgH YAC (5) and the 5' end of coslg6 (35) confirmed the overlap and identified a novel region of 11 kb. The failure of previous attempts to clone the C δ -C γ 3 contig in cosmids or YACs can now be fully explained by the extensive repetitiveness of the intronic sequence. Such repetitive regions are prone to deletion through homologous recombination when cloned in yeast (65). It is estimated that Alu-like repeat sequences are represented on average every 4 kb throughout the genome (66, 67). In the interval from C δ m2 to C γ 3, 11 Alu-like repeats were identified in a 15 kb region. In contrast, the number of Alu motifs identified in the 950 kb region containing the variable genes of the human IgH locus was much less than expected by random distribution (68). The presence of Alu repeat elements immediately adjacent to proto-oncogene translocations has led to the suggestion that frequent Alu motifs may predispose a region as a hot spot for recombination (69, 70). Indeed, the MstII-like sequences, identified in tandem in the C δ -C γ 3 interval, align with the consensus sequence of transposon-like elements in the human genome (39, 40). The instability of the region is further supported by linkage data, which indicate a lack of association between C δ and C γ 3 (7) and that certain leukemias have deletion boundaries in the C δ -C γ 3 region (9). Thus, translocations near the enhancer-silencer array in the C δ -C γ 3 interval may result in transcriptional alterations of the rearranged genes or loci leading to a malignant phenotype of the cell subset where enhancer activity can be identified. Interestingly, chromosomal translocations in Burkitt's lymphoma where *c-myc* expression is deregulated by linkage to a known enhancer may represent tumors of a developmental stage in which the enhancer is active.

A Factor binding site cluster

The frequency of potential transcription factor binding sites in the 21 kb of the C δ -C γ 3 interval region sequenced was unexpected. Using the default scores for the analysis, 0.75 for core similarity and 0.85 for matrix similarity (41) identified too many motifs to be useful. Our analysis used scores for the core similarity of 1 and matrix similarity of 0.90. This higher score allowed the unambiguous identification of multiple motifs for 9 transcription factor binding sites, five of which are recognised by proteins that have shown to increase transcription in lymphocytes (Ikaro, E47, Oct-1, USF and Myc/Max) and four motifs shown to be recognised by transcription silencer or repressor proteins (DeltaEF1, Gfi-1, E4BP4 and C/EBPbeta). It has been shown that the repressor proteins Delta-EF1 and Gfi-1 interact with elements of the E μ enhancer (59, 58). However, it is not obvious how the lymphocyte-specific enhancer and repressor activity identified by functional analysis of C δ - γ 3 interval fragments relates to this accumulation of potential transcription factor binding motifs. Core sequence motifs for factor binding sites found in E μ also occur frequently in this novel enhancer region and, indeed, in the whole 21 kb region analysed (see Fig. 3). That all 9 binding sites appear frequently throughout the E δ - γ 3 interval makes it impossible to predict the activity of a particular region solely based on the nucleotide sequence. Furthermore, besides short sequence motifs no homology to draw conclusions about functional similarity was found between the MluI-HindIII fragment accommodating E δ - γ 3 and the E μ or 3' α enhancers (71-74). Similarly, the region responsible for the transcription silencer activity could not be deduced from sequence comparison. However, because of the significance of the functional activity identified in the C δ - γ 3 interval it is unlikely that the motifs in this cluster are randomly distributed. In addition, recognition sequences essential for suppressing the function of the mouse 3' enhancer have been reported (30), but were not evident in the sequenced region. Sequence comparison of human E δ - γ 3 with the available mouse δ - γ 3 interval sequence did not allow identification of an equivalent mouse enhancer; however, a reason for this could be the apparent sequence gaps.

An essential role of the C δ -C γ 3 interval in early lymphocyte development

The location of the C δ -C γ 3 interval means that it will be deleted after switching from C μ to other isotypes. This implies that the regulatory activity of this region must be important during early developmental steps, which is supported by our finding that E δ - γ 3 enhancer control is operative at the pro/pre B-cell stage (see Fig. 7). Reporter gene assays suggest that the C δ -C γ 3 interval region provides strong B-cell specific enhancer and repressor function. The strength of E δ - γ 3, position 5885-7185, can be 2-fold greater than E μ enhancer activity in pre B-cells, but unlike E μ and E α 3' the δ - γ 3 interval enhancer does not exhibit any activity in mature B-cells. Interestingly, E δ - γ 3 activity is solely B-cell specific unlike that of E μ which shows some activity in T-cells at the developmental timing of rearrangement (75). At developmental stages where neither the E μ nor the E3' α enhancer was particularly active by itself, enhancer combinations identified synergistic transcriptional activity (76). A different picture emerged when C δ - γ 3 interval fragments in combination with E μ were transfected (Fig. 5). Here individual enhancer function remained cell type specific rather than synergistically increased; in E δ - γ 3+E μ constructs the activity equalled that of E δ - γ 3 in pre B-cells whilst E μ levels were obtained in plasma cells. The identified silencer extinguished both enhancers at the pre B-cell stage which suggests a complex, yet to be explored, regulatory function of elements in the E δ - γ 3 interval which appear to coordinate stage specific H chain activation. When linked to a β -globin gene (that does not contain any cell-type specific intragenic regulatory elements active in hematopoietic cells) and assayed in transgenic mice, E δ - γ 3 is a B-cell specific transcription enhancer element active during B-cell development in the bone marrow. This pattern of activity complements the transcriptional activities of E μ and E3' α , contributory to V to DJ joining, switching and H chain expression (18, 21, 77, 78), and may suggest a role of E δ - γ 3 in heavy chain activation and/or initiation of DNA rearrangement. A view that the presence of several enhancers in the Ig loci simply reflects redundancy cannot be supported with these results which put the functional activity of the IgH enhancers in a

possible order. Starting with the earliest; E δ - γ 3 may be important for H chain activation with initiation of DNA recombination; E μ may then complete the joining process to allow H chain expression; E μ may also be involved in facilitating isotype switching; E α 3' may complete the switching process, which also deletes E μ and E δ - γ 3, and may have a role in influencing expression.

The high frequency of transcription factor binding sites and the functional activity of the C δ -C γ 3 intron, which includes an enhancer-silencer array, is reminiscent of the locus control regions (LCRs) described for the globin locus (79, 80). It is characteristic of LCRs that they are essential for the correct activation of a locus to ensure physiological expression levels are obtained. In transgenic mice carrying part of the human IgH locus, high level expression of the transgene independent of copy number and integration site was not achieved (5). This suggests that neither the E μ nor the 3' enhancer region are sufficient in themselves to ensure the full activity of a single copy translocus. In transgenic mice it will be interesting to see if a translocus that includes a complete C δ -C γ 3 interval allows correct chromatin opening and gene activation. Identification of an equivalent region in the mouse and its removal by a knock-out approach may shed further light on IgH locus activation and the DNA recombination processes which are still poorly understood.

Construction and expression analysis of the human IgH YAC has been described in Nicholson *et al*, J. Immunol., 163, 6898-6906, 1999, and techniques to manipulate YACs by extension have been described by Popov *et al*, Gene, 177, 195-201, 1996.

The extension of the hulgH YAC by adding a (γ) 3 constant (C) region allows to study isotype switching. We used two strategies to obtain a human IgHG3 YAC: 1) addition to the γ 3 region on a cosmid to the hulgH YAC and 2) cloning of the authentic ~50 kb region between C δ and C γ 3 in pBAC and elongating the hulgHG3 cosmid YAC by addition of this region. This produced an ~300 kb human IgH region containing the authentic germ line region from VH2-5 to downstream of C γ 3.

In detail, the experiments were done in the following way:

- 1) hulgH YAC-containing yeast cells were co-transfected with BssHII linearised coslg6 (the C γ 3 containing cosmid produced by Flanagan and Rabbitts, *Nature*, 300, 709-713, 1983) and a non-centromeric YAC arm replacement containing ADE2 as selectable marker (Markie *et al*, *Somat. Cell. Mol. Genet.*, 19, 161-169, 199). This allowed tandem integration and selection of modified YACs. IgG3 YACs were initially identified by PCR and further analysed by normal gel electrophoresis and pulsed field gel electrophoresis on Southern blots. IgH yeast clones containing the complete γ 3 cosmid region in correct transcriptional orientation, integrated in the predicted way, were used in protoplast fusion of yeast and ES cells. The resulting hulgHG3 ES cell clones were further analysed for gene content. Four different hulgHG3 clones modified as shown in Fig. 8, were used to produce chimeric mice and also resulted in germ line transmission mice. Expression of human IgG3 was found in all four founders but the levels identified in ELISA assays were relatively low (ng/ml). Breeding into the μ MT background (a mouse strain with silenced mouse heavy chain locus, Kitamura *et al*, *Nature*, 350, 423-426, 1991) may give more efficient human IgG3 expression.
- 2) The human IgHG3 YAC with the integrated cosmid DNA contains a deletion of vital regulatory sequences identified on a pBAC clone which covers the rather unstable region between C δ and C γ 3 (see above). In order to produce a YAC with the authentic region from the VH cluster downstream of the γ constant region genes we co-transformed the cosmid containing γ 3 YAC with the MluI linearised pBAC and the HIS5 gene as a selectable marker (Nishiwaki *et al*, *Mol. Gen. Genet.*, 208, 159-167, 1987). The HIS5 gene was subcloned into URA3, a gene present on the non-centromeric YAC arm. Both genes/regions, pBAC and HIS3 in URA3, allow homologous integration into the YAC and correct integration was identified by PCR and Southern blot (Fig. 9).
- 9). YAC-ES cell protoplast fusion was carried out and the resulting clones were analysed by Southern blot and PCR. Two clones were used to obtain chimeric mice which are currently breeding to obtain germ line transmission.

References

1. Hofker, M. H., M. A. Walter and D. W. Cox. 1989. Complete physical map of the human immunoglobulin heavy chain constant region gene complex. *Proc. Natl. Acad. Sci. USA* 86:5567.
2. Mendez, M. J., H. Abderrahim, M. Noguchi, N. E. David, M. C. Hardy, L. L. Green, H. Tsuda, S. Yoast, C. E. Maynard-Currie, D. Garza, R. Gemmill, A. Jakobovits, and S. Klapholz. 1995. Analysis of the structural integrity of YACs comprising human immunoglobulin genes in yeast and in embryonic stem cells. *Genomics* 26:294.
3. Chen, C. and B. K. Birshtein. 1997. Virtually identical enhancers containing a segment of homology to murine 3' IgH-E(hs1,2) lie downstream of human Ig C α 1 and C α 2 genes. *J. Immunol.* 159:1310.
4. Kang, H. K. and D. W. Cox. 1996. Tandem repeats 3' of the IGHA genes in the human immunoglobulin heavy chain gene cluster. *Genomics* 35:189.
5. Brüggemann, M. and M. S. Neuberger. 1996. Strategies for expressing human antibody repertoires in transgenic mice. *Immunol. Today* 17:391.
6. Green, L. L., M. C. Hardy, C. E. Maynard-Currie, H. Tsuda, D. M. Louie, M. J. Mendez, H. Abderrahim, M. Noguchi, D. H. Smith, Y. Zeng, N. E. David, H. Sasai, D. Garza, D. G. Brenner, J. F. Hales, R. P. McGunness, D. J. Capon, S. Klapholz and A. Jakobovits. 1994. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. *Nature Genetics* 7:13.
7. Bengler, J. C. and D. W. Cox. 1989. Polymorphisms of the immunoglobulin heavy-chain delta gene and association with other constant-region genes. *Am. J. Hum. Genet.* 45:606.
8. Walter, M. A. and D. W. Cox. 1991. Nonuniform linkage disequilibrium within a 1,500-kb region of the human immunoglobulin heavy-chain complex. *Am. J. Hum. Genet.* 49:917.
9. Dyer, M. J. S., J. M. Heward, V. J. Zani, V. Buccheri and D. Catovsky. 1993. Unusual deletions within the immunoglobulin heavy-chain locus in acute leukemias. *Blood* 82:865.

10. Shimizu, A., N. Takahashi, Y. Yaoita and T. Honjo. 1982. Organization of the constant-region gene family of the mouse immunoglobulin heavy chain. *Cell*. 28:499.
11. Cockerill, P. N. 1990. Nuclear matrix attachment occurs in several regions of the IgH locus. *Nucl. Acids Res.* 18:2643.
12. Lieberman, R., J. Ong, X. Shi and L. A. Eckhardt. 1995. Immunoglobulin gene transcription ceases upon deletion of a distant enhancer. *EMBO J.* 14:6229.
13. Michaelson, J. S., M. Singh, C. M. Snapper, W. C. Sha, D. Baltimore and B. K. Birshtein. 1996. Regulation of 3' IgH enhancers by a common set of factors, including κ B-Binding proteins. *J. Immunol.* 156:2828.
14. Rao, E., G. Gang and R. Sen. 1997. The three-protein-DNA complex on a B cell-specific domain of the immunoglobulin μ heavy chain gene enhancer. *J. Biol. Chem.* 272:6722.
15. Max, E. E. 1999. Immunoglobulins: molecular genetics. in *Fundamental Immunology, Fourth Edition*, ed. W. E. Paul, publ. Lippincott-Raven, Philadelphia, pp. 111-182.
16. Grant, P. A., V. Arulampalam, L. Ahrlund-Richter and S. Pettersson. 1992. Identification of Ets-like lymphoid specific elements within the immunoglobulin heavy chain 3' enhancer. *Nucl. Acids Res.* 20: 4401.
17. Arulampalam, V., L. Eckhardt and S. Pettersson. 1997. The enhancer shift: a model to explain the developmental control of IgH gene expression in B-lineage cells. *Immunol. Today* 18:549.
18. Cogné, M., R. Lansford, A. Bottaro, J. Zhang, J. Gorman, F. Young, H. Cheng and F.-W. Alt. 1994. A class switch control region at the 3' end of the immunoglobulin heavy chain locus. *Cell* 77:737.
19. Ernst, P. and S. T. Smale. 1995. Combinatorial Regulation of Transcription II: The immunoglobulin μ heavy chain gene. *Immunity* 2:427.
20. Henderson, A. and K. Calame. 1998. Transcriptional Regulation During B Cell Development. *Annu. Rev. Immunol.* 16:163.

21. Serwe, M. and F. Sablitzky. 1993. V(D)J recombination in B cells is impaired but not blocked by targeted deletion of the immunoglobulin heavy chain intron enhancer. *EMBO J.* 12:2321.
22. Kim, U.-J., B. W. Birren, T. Slepak, V. Mancino, C. Boysen, H.-L. Kang, M. I. Simon and H. Shizuya. 1996. Construction and characterization of a human bacterial artificial chromosome library. *Genomics* 34:213.
23. Eagle, H. 1955. Propagation in a fluid medium of a human epidermoid carcinoma strain, KB. *Proc. Soc. Exp. Biol.* 89:362.
24. Sheng, Y., V. Mancino and B. Birren. 1995. Transformation of *Escherichia coli* with large DNA molecules by electroporation. *Nucl. Acids Res.* 23:1990.
25. Bützler, C., X. Zou, A. V. Popov and M. Brüggemann. 1997. Rapid induction of B-cell lymphomas in mice carrying a human IgH/c-myc YAC. *Oncogene* 14:1383.
26. Brüggemann, M., G. T. Williams, C. I. Bindon, M. R. Clark, M. R. Walker, R. Jefferis, H. Waldmann and M. S. Neuberger. 1987. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. *J. Exp. Med.* 166:1351.
27. Meffre, E., M. Fougereau, J.-N. Argenson, J.-M. Aubaniac and C. Schiffl. 1996. Cell surface expression of surrogate light chain (Ψ L) in the absence of μ on human pro-B cell lines and normal pro-B cells. *Eur. J. Immunol.* 26:2172.
28. Sideras, P., L. Nilsson, K. B. Islam, I. Zalcberg, Q. L. Freihof, A. Rosén, G. Juliusson, L. Hammarström and C. I. E. Smith. 1992. Transcription of unrearranged Ig H chain genes in human B cell malignancies. *J. Immunol.* 149:244.
29. Weiss, A., R. L. Wiskocil and J. D. Stobo. 1984. The role of T3 surface molecules in the activation of human T cells: A two-stimulus requirement for IL2 production reflects events occurring at a pre-translational level. *J. Immunol.* 133:123.
30. Singh, M. and B. K. Birshtein. 1993. NF-HB (BSAP) is a repressor of the murine immunoglobulin heavy-chain 3'α enhancer at early stages of B-cell differentiation. *Mol. Cell. Biol.* 13:3611.

31. Meyer, K. B., Y.-M. Teh and M. S. Neuberger. 1996. The Ig κ 3' enhancer triggers gene expression in early B lymphocytes but its activity is enhanced on B cell activation. *Int. Immunol.* 8:1561.
32. Gordon, J. W. and F. H. Ruddle. 1983. Gene transfer into mouse embryos: production of transgenic mice by pronuclear injection. *Methods Enzymol.* 101:411.
33. Palomo, C., X. Zou, I. C. Nicholson, C. Bützler and M. Brüggemann. 1999. B-cell tumorigenesis in mice carrying a YAC-based IgH/c-myc translocus is independent of E μ . *Cancer Res.* 59:5625.
34. Popov, A. V., X. Zou, J. Xian, I. C. Nicholson and M. Brüggemann. 1999. A human immunoglobulin λ locus is similarly well expressed in mice and humans. *J. Exp. Med.* 189:1611.
35. Flanagan, J. G. and T. H. Rabbitts. 1982. Arrangement of human immunoglobulin heavy chain constant region genes implies evolutionary duplication of a segment containing γ , ϵ and α genes. *Nature* 300:23.
36. Huck, S., P. Fort, D.-H. Crawford, M.-P. Lefranc and G. Lefranc. 1986. Sequence of a human immunoglobulin gamma 3 heavy constant region gene; comparison with the other human C γ genes. *Nucl. Acids Res.* 14:1779.
37. Deihinger, P. L.; D. J. Jolly, C. M. Rubin, T. Friedmann and C. W. Schmid. 1981. Base sequence studies of 300 nucleotide renatured repeated human DNA clones. *J. Mol. Biol.* 151:17.
38. Boeke, J. D. 1997. LINEs and Alus-the poly A connection. *Nat. Gen.* 16:6.
39. Fields, C. A., D. L. Grady and R. K. Moyzis. 1992. The human THE-LTR(O) and MstII interspersed repeats are subfamilies of a single widely distributed highly variable repeat family. *Genomics* 13:431.
40. Merfmer, B., M. Colb and T. G. Krontiris. 1987. A family of short, interspersed repeats is associated with tandemly repetitive DNA in the human genome. *Proc. Natl. Acad. Sci. USA* 84:3320.
41. Frech, K., K. Quandt and T. Werner. 1997. Finding protein-binding sites in DNA sequences: the next generation. *TIBS* 22:103.

42. Ghosh, D. 1993. Status of the transcription factors database (TFD). *Nucl. Acids Res.* 21:3117.
43. Fitzsimmons, D. and J. Hagman. 1996. Regulation of gene expression at early stages of B-cell and T-cell differentiation. *Curr. Opin. Immunol.* 8: 166.
44. Glimcher, L. H. and H. Singh. 1998. Transcription factors in lymphoid development - T and B cells get together. *Cell* 96:13.
45. Bendall, A. J. and P. L. Molloy. 1994. Base preferences for DNA binding by the bHLH-zip protein USF: effects of MgCl₂ on specificity and comparison with binding of Myc family members. *Nucl. Acids Res.* 22:2801.
46. Georgopoulos, K. 1997. Transcription factors required for lymphoid lineage commitment. *Curr. Opin. Immunol.* 9:222.
47. Grandori, C. and R. N. Eisenman. 1997. Myc target genes. *TIBS* 22: 177.
48. Kadesch, T. 1992. Helix-loop-helix proteins in the regulation of immunoglobulin gene transcription. *Immunol. Today* 13:31.
49. Li, P., X. He, M. R. Gorrero, M. Mok, A. Aggarwal and M. G. Rosenfeld. 1993. Spacing and orientation of bipartite DNA-binding motifs as potential functional determinants for POU domain factors. *Genes Dev.* 7: 2483.
50. Zwilling, S., A. Annweiler and T. Wirth. 1994. The POU domains of the Oct1 and Oct2 transcription factors mediate specific interaction with TBP. *Nucl. Acids Res.* 22:1655.
51. Solomon, D. L. C., B. Amati and H. Land. 1993. Distinct DNA binding preferences for the c-Myc/Max and Max/Max dimers. *Nucl. Acids Res.* 21: 5372.
52. Molnár, A. and K. Georgopoulos. 1994. The Ikaros gene encodes a family of functionally diverse zinc finger DNA-binding proteins. *Mol. Cell. Biol.* 14:8292.
53. Klug, C. A., S. J. Morrison, M. Masek, K. Hahn, S. T. Smale and I. L. Weissman. 1998. Hematopoietic stem cells and lymphoid progenitors express different Ikaros isoforms, and Ikaros is localized to heterochromatin in immature lymphocytes. *Proc. Natl. Acad. Sci. USA* 95:657.
54. Cowell, I. G., A. Skinner and H. C. Hurst. 1992. Transcriptional repression by a novel member of the bZIP Family of transcription factors. *Mol. Cell. Biol.* 12:3070.

55. Lu, M., J. Seufert and J. F. Hebener. 1997. Pancreatic beta-cell-specific repression of insulin gene transcription by CCAAT/enhancer-binding protein beta. Inhibitory interactions with basic helix-loop-helix transcription factor E47. *J. Biol. Chem.* 272:28349.
56. Sekido, R., K. Murai, J.-I. Funahashi, Y. Kamachi, A. Fujisawa-Sehara, Y.-I. Nabeshima and H. Kondoh. 1994. The δ -Crystallin enhancer-binding protein δ EF1 is a repressor of E2-box-mediated gene activation. *Mol. Cell Biol.* 14:5692.
57. Sekido, R., T. Takagi, M. Okanami, H. Moride, M. Yamamura, Y. Higashi and H. Kondoh. 1996. Organisation of the gene encoding transcriptional repressor deltaEF1 and cross-species conservation of its domains. *Gene* 16:227.
58. Zweidler-McKay, P. A., H. L. Grimes, M. M. Flubacher and P. N. Tsichlis. 1996. Gfi-1 Encodes a Nuclear Zinc finger protein that binds DNA and functions as a transcriptional repressor. *Mol. Cell Biol.* 16:4024.
59. Grimes, H. L., T. O. Chan, P. A. Zweidler-McKay, B. Tong and P. N. Tsichlis. 1996. The Gfi-1 proto-oncoprotein contains a novel transcriptional repressor domain, SNAG, and inhibits G1 arrest induced by interleukin-2 withdrawal. *Mol. Cell Biol.* 16:6263.
60. Enjoji, M. 1994. Human HE2 (μ B) and μ A motifs show the same function as whole IgH intronic enhancer in transgenic mice. *Mol. Cell. Biochem.* 137: 33.
61. Stevens, S., P. Ordentlich, R. Sen and T. Kadesch. 1996. HMG box-activating factors 1 and 2, two HMG box transcription factors that bind the human Ig heavy chain enhancer. *J. Immunol.* 157:3491.
62. Hardy, R. R., C. E. Carmack, S. A. Shinton, J. D. Kemp and K. Hayakawa. 1991. Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. *J. Exp. Med.* 173:1213.
63. ten Boekel, E., F. Melchers and A. Rolink. 1995. The status of Ig loci rearrangements in single cells from different stages of B cell development. *Int. Immunol.* 7:1013.
64. Wang, M., X.-N. Chen, S. Shouse, J. Manson, Q. Wu, R. Li, J. Wrestler, D. Noya, Z.-G. Suñ, J. Korenberg and E. Lai. 1994. Construction and

characterization of a human chromosome 2-specific BAC library. *Genomics* 24:527.

65. Le, Y. and M. J. Dobson. 1997. Stabilization of yeast artificial chromosome clones in a rad54-3 recombination-deficient host strain. *Nucl. Acids Res.* 25:1248.

66. Sherry, S. T., H. C. Harpending, M. A. Batzer and M. Stoneking. 1997. Alu evolution in human populations: using the coalescent to estimate effective population size. *Genetics* 147:1977.

67. Yulug, I. G., A. Yulug and E. M. C. Fisher. 1995. The frequency and position of Alu repeats in cDNAs, as determined by database searching. *Genomics* 27:544.

68. Matsuda, F., K. Ishii, P. Bourvagnet, K. Kumai, H. Hayashida, T. Miyata and T. Honjo. 1998. The complete nucleotide sequence of the human immunoglobulin heavy chain variable region locus. *J. Exp. Med.* 188:2151.

69. Jeffs, A. R., S. M. Benjes, T. L. Smith, S. J. Sowerby and C. M. Morris. 1998. The BCR gene recombines preferentially with Alu elements in complex BCR-ABL translocations of chronic myeloid leukaemia. *Hum. Mol. Gen.* 7:767.

70. Willis, T. G., D. M. Jadayel, L. J. A. Coignet, M. Abdul-Rauf, J. G. Treleaven, D. Catovsky and M. J. Dyer. 1997. Rapid molecular cloning of rearrangements of the IGHJ locus using long-distance inverse polymerase chain reaction. *Blood* 90:2456.

71. Carter, R. S., P. Orendtlich and T. Kadesch. 1997. Selective utilisation of basic helix-loop-helix-leucine zipper proteins at the immunoglobulin heavy-chain enhancer. *Mol. Cell. Biol.* 17:18.

72. Glozak, M. A. and B. Blomberg. 1996. The human λ immunoglobulin enhancer is controlled by both positive elements and developmentally regulated negative elements. *Mol. Immunol.* 33:427.

73. Gumucio, D. H., H. Heilstedt-Williamson, T. A. Gray, S. A. Tarié, D. A. Shelton, D. A. Tagle, J. L. Slightom, M. Goodman and F. S. Collins. 1992. Phylogenetic footprinting reveals a nuclear protein which binds to silencer sequences in the human γ and ϵ globin gene. *Mol. Cell. Biol.* 12:4919.

74. Scheuermann, R. H. and U. Chen. 1989. A developmental-specific factor binds to suppressor sites flanking the immunoglobulin heavy-chain enhancer. *Genes Dev.* 3:1255.
75. Cook, G. P., K. B. Meyer, M. S. Neuberger and S. Pettersson. 1995. Regulated activity of the IgH intron enhancer ($E\mu$) in the T lymphocyte lineage. *Int. Immunol.* 7: 89.
76. Ong, J., S. Stevens, R. G. Roeder and L. A. Eckhardt. 1998. 3' IgH Enhancer elements shift synergistic interactions during B cell development. *J. Immunol.* 160:4896.
77. Bottaro, A., F. Young, J. Chen, M. Serwe, F. Sablitzky and F. W. Alt. 1998. Deletion of the IgH intronic enhancer and associated matrix-attachment regions decreases, but does not abolish, class switching at the μ locus. *Int. Immunol.* 10:799.
78. Manis, J. P., N. van der Stoep, M. Tian, R. Ferrini, L. Davidson, A. Bottaro and F. W. Alt. 1998. Class switching in B cells lacking 3' immunoglobulin heavy chain enhancers. *J. Exp. Med.* 188:1421.
79. Fraser, P. and F. Grosveld. 1998. Locus control regions, chromatin activation and transcription. *Cur. Opin. Cell Biol.* 10:361.
80. Townes, T. M. and R. R. Behringer. 1990. Human globin locus activation region (LAR): role in temporal control. *Trends in Genetics* 6:219.
81. Hahm, K., P. Ernst, K. Lo, G. S. Kim and S. T. Smale. 1994. The lymphoid transcription factor LyF-1 is encoded by specific, alternatively spliced mRNAs derived from the Ikaros gene. *Mol. Cell. Biol.* 14:7111.
82. Lo, K., N. R. Landau and S. T. Smale. 1991. LyF-1, a transcriptional regulator that interacts with a novel class of promoters for lymphocyte-specific genes. *Mol. Cell. Biol.* 11:5229.
83. Sigvardsson, M., M. O'Riordan and R. Grosschedl. 1997. EBF and E47 collaborate to induce expression of the endogenous immunoglobulin surrogate light chain genes. *Immunity* 7:25.
84. Staudt, L. M. and M. J. Lenardo. 1991. Immunoglobulin Gene Transcription. *Annu. Rev. Immunol.* 9:373.

85. Verrijzer, C. P., M. J. Alkema, W. W. van Weperen, H. C. Van Leeuwen, M. J. J. Strating and P. C. van der Vliet. 1992. The DNA binding specificity of the bipartite POU domain and its subdomains. *EMBO J.* 11:4993.
86. Ikushima, S., T. Inukai, T. Inaba, S. D. Nimer, J. L. Cleveland and A. T. Cook. 1997. Pivotal role for the NFIL3/E4BPA transcription factor in interleukin-3-mediated survival of pro-B lymphocytes. *Proc. Natl. Acad. Sci. USA* 94:2609.
87. Zhang, W., J. Zhang, M. Kornuc, K. Kwan, R. Frank and S. D. Nimer. 1995. Molecular cloning and characterization of NF-IL3A, a transcriptional activator of the human interleukin-3 promoter. *Mol. Cell. Biol.* 15:6055.
88. Saisanit, S. and X.-H. Sun. 1997. Regulation of the pro-B-cell-specific enhancer of the Id1 gene involves the C/EBP family of proteins. *Mol. Cell. Biol.* 17:844.

Abbreviations used herein: BAC, bacterial artificial chromosome; LCR, locus control region; MAR, matrix association region; PFGE, pulsed field gel electrophoresis; YAC, yeast artificial chromosome.

Figure legends

FIGURE 1. Location of the pBAC clone pHu3' δ - γ 3 spanning the gap in the C δ -C γ 3 interval region of the human IgH locus. A, Restriction analysis shows that the 48 kb MluI fragment present in pHuH3' δ - γ 3 (bottom) aligns with the 3' end of the HuIgH YAC (middle, left) and the 5' end of Cosmid Ig6 (middle, right), with the gap indicating the previously uncloned region of the C δ -C γ 3 interval (top). The hatched region in pHuH3' δ - γ 3 was sequenced and fragments were analysed in reporter gene assays. M, MluI; X, XhoI; B, BamHI; H, HindIII; E, EcoRI. (▼) 400 bp EcoRI fragment of plasmid pM5-1-23; (●) γ 3 gene probe; (◆) 500 bp SspI-BamHI fragment from pHuH3' δ - γ 3. B, Hybridization of BamHI or HindIII digested human sperm DNA and pHuH3' δ - γ 3 DNA with the 500 bp SspI-BamHI fragment derived from pHuH3' δ - γ 3 confirms that the isolated fragment linking the C δ -C γ 3 gap is in the correct germline configuration.

FIGURE 2. Analysis of nucleotide sequence of pHuH3' δ - γ 3. A, Dot Plot of self-alignment of the 5' 21 kb of the cloned region between C δ and C γ 3 starting at the 5' MluI site (see Fig. 1 for restriction sites) using the MacVector 6.01 program

(Oxford Molecular, Oxford, UK). The location of the eleven Alu-repeat-like sequences are indicated as boxes below the matrix with arrows indicating the orientation of the repeat. Three other regions of repetitive sequence are indicated by vertical arrows. Region 1 comprises three consecutive MstII-like elements. Region 2 comprises a region of 21 repeats of "CT" followed by 15 repeats of "AT". Region 3 comprises several complete and fragmented Alu motifs, as shown in B. B, Detail of the Alu motifs and fragments in region 3. The orientation of the Alu motif, indicated by a shaded box followed by an unshaded box, is indicated by arrows. The combination of a shaded box followed by an unshaded box forms an Alu-repeat-like element (large filled arrows). Separate unshaded boxes represent incomplete Alu motifs in the orientation indicated.

FIGURE 3. Location of transcription factor recognition motifs. The sequence of the 5' 20696 bp of the cloned fragment was compared to the TRANSFAC database using MatInspector, with a score of 1.0 for core similarity and ≥ 0.9 for matrix similarity (41). Restriction sites are indicated for alignment (see Fig. 1); MluI (M), BamHI (B) and HindIII (H). The potential transcription factor binding sites are indicated by open boxes. Factors which may enhance transcription in lymphocytes include Ikaros (81, 82, 52), E47 (83), Oct-1 (84, 85), USF (45), and Myc/Max (51). Factors which may suppress transcription include DeltaEF1 (56), Gfi-1 (58), E4BP4 (54, 86, 87), and C/EBPbeta (88).

FIGURE 4. Transcription enhancer activity of fragments obtained from the MluI-BamHI region of pHuIgH3' δ - γ 3. A, Location of the subcloned fragments (from position 4510, 5555, 5885, 6461 and 6884 down to position 7185) with the shaded region marking the MluI-BamHI fragment (1-B), position 1 to 7185. The subcloned fragments were analysed using luciferase reporter gene assays to detect enhancer activity in B, murine pre B-cells (3-1, black bars) and human pre B-cells (NALM-6, striped bars) and C, murine plasma cells (MPC11, shaded bars) and human plasma cells (DG-75, lined bars). Experiments using murine 18-81 pre B-cells gave similarly positive results. No enhancer dependent activity was found for AH murine plasma cells, the human T lymphoblast cell line Jurkat or human KB fibroblasts (data not shown). Bars indicate luciferase activity for the

different fragments: 4510-B, 5555-B, 5885-B, 6461-B and 6884-B which are different length 3' clones obtained by exonuclease digest of the 1-B fragment subcloned in pGL3 (see Fig. 5). The luciferase activities were normalised to the β -galactosidase activity of the co-transfected plasmid and expressed as fold-increase. Values are averages of four to six independent experiments with at least two different DNA preparations. The range of standard deviation is shown in Fig. 5. Values were also determined for pGL3 vector alone, for pGL3 containing the SV40 promoter, and for pGL3 containing human E μ .

FIGURE 5. Transcriptional activity of various pHuIgH3' δ - γ 3 fragments in combination with E μ . *A*, Schematic diagram of the luciferase reporter gene construct with location of the insert fragments and position of E μ . *B*, pHuIgH3' δ - γ 3 map and location of the subcloned fragments (left). Transcriptional activity, with standard error indicated, of fragments 1 (MluI-HindIII), 2 (MluI-BamHI), 3 (HindIII) and 4 (BamHI) with (shaded box) and without E μ (white box) was determined in pre B-cells and plasma cells. Assay details are described in Fig. 4 and in Materials and Methods.

FIGURE 6. Transgene construct, transgenic mouse identification and transcription analysis. *A*, Structure of the transgene linking E δ - γ 3 (position 5885-7185, see Fig. 4) and a human β -globin reporter gene (31). *B*, Southern blot hybridization of NcoI digested tail DNA from transgenic founders carrying the E δ - γ 3- β -globin transgene. The internal NcoI fragment is ~1.2 kb and head to tail integration produces a ~3.2 kb band. The copy number (high copy number founder 3823, low copy number founder 3832) is reflected by the signal intensity. *C*, Northern blot hybridization of different tissue samples as indicated (BM, bone marrow; PPs, Peyer's patches) with the β -globin transgene (β G) and an actin probe (33) as standard. A transgene specific hybridization signal for β -globin was only found for bone marrow RNA. Human blood and normal mouse spleen RNA served as a control.

FIGURE 7. Molecular characterization of B-cell subpopulations at various stages of development. *A*, Schematic presentation of B-cell development from

stem cell to antibody secreting plasma cell. DNA rearrangement steps for the heavy chain (D to J_H and V_H to DJ_H) and the light (L) chain (V_L to J_L) leading to surface expression and secretion of Ig are indicated. L chain rearrangement is preceded by expression of surrogate L chain (Ψ_{LC}) and gp130/gp50. Expression of the differentiation stage specific surface markers, B220, CD19, CD25, *c-kit* and CD43, is indicated by arrow bars. B, Flow cytometric isolation of *c-kit*⁺ CD19⁻ [1], *c-kit*⁺ CD19⁺ [2], CD43⁺ B220⁻ [3], CD43⁺ B220⁺ [4], CD25⁺ CD19⁺ [5] and IgM⁺ IgD⁻ [6] bone marrow B-cell populations. C, RT-PCR amplification of sorted cell populations 1-6, bone marrow (bm) and human red cells (HRC) with a combination of β-globin (βG) and HPRT primers as indicated. A strong β-globin PCR product was found in B220⁺ cells from the pro/pre B-cell type up to the immature B-cell. High copy number mice were used for the analysis shown but low copy number mice gave essentially the same result.

CLAIMS

1. An artificial chromosome including a region, between C δ and C γ 3, of the human IgH locus, or a functional part thereof.
2. A chromosome according to claim 1, which is a bacterial, yeast, eukaryotic or mammalian chromosome.
3. A non-human animal capable of producing human antibodies, and which has been transformed to include a region, between C δ and C γ 3, of the human IgH locus, or a functional part thereof.
4. An animal according to claim 3, which is a rodent, sheep, horse, pig, goat, rabbit, chicken or cow.
5. A repertoire of human antibodies, obtainable from an animal according to claim 3.
6. A repertoire of heavy chains, obtainable from an animal according to claim 3.
7. A polynucleotide comprising at least a functional enhancer or other expression modifier present in the region, between C δ and C γ 3, of the IgH locus, and a heterologous gene under the control of the modifier.
8. A polynucleotide according to claim 6, wherein the modifier comprises E δ - γ 3.



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

COPY OF PAPERS
ORIGINALLY FILED

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

RECEIVED
MAY 20 2002
TC 1700

Signed

Andrew Gurney

Dated 21 FEB 2002

100
100
100
100
100

100
100
100
100
100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100




FIG. 1

1. The first part of the report discusses the general situation of the company and the results of the audit. It also mentions the scope of the audit and the methods used.

2. The second part of the report discusses the results of the audit in detail. It mentions the findings of the audit and the recommendations made by the auditor.

3. The third part of the report discusses the conclusions of the audit and the actions that need to be taken to improve the company's financial position.

4. The fourth part of the report discusses the auditor's opinion on the company's financial statements and the reasons for that opinion.

5. The fifth part of the report discusses the auditor's recommendations for the company's future financial management.

1. The first part of the report discusses the general situation of the company and the results of the audit. It also mentions the scope of the audit and the methods used.

2. The second part of the report discusses the results of the audit in detail. It mentions the findings of the audit and the recommendations made by the auditor.

3. The third part of the report discusses the conclusions of the audit and the actions that need to be taken to improve the company's financial position.

4. The fourth part of the report discusses the auditor's opinion on the company's financial statements and the reasons for that opinion.

5. The fifth part of the report discusses the auditor's recommendations for the company's future financial management.




FIG. 2

214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000



THE UNIVERSITY OF CHICAGO

LIBRARY OF THE UNIVERSITY OF CHICAGO
1100 EAST 58TH STREET
CHICAGO, ILL. 60637

THE UNIVERSITY OF CHICAGO
LIBRARY OF THE UNIVERSITY OF CHICAGO
1100 EAST 58TH STREET
CHICAGO, ILL. 60637




FIG. 4

7: 4

[illegible]

...and the ...





FIG. 5

L. 5







FIG. 6

Fig 6






FIG. 7



Human IgH3 Translocus



